Boston, MA 10/25/2013 (wallstreetpr) – That Stereotaxis Inc (NASDAQ:STXS) has had unimpressive increase in net income over some time now makes it a candidate for sell. The highlights in its net income indicate that over the past 12 months, it has under formed compared to the industry average. In that period, its net profit has reduced by 207.1% which reflects a drop from $2.81 million in net profit a year ago to $-3.01 million.
Over the past 2 years, STXS has had a weakening per share earnings trend. The steep decline in per share earnings has seen the company report more on the negative in the previous quarters spanning 2 fiscal years. While earnings per share in this stock have not been very encouraging, it can be seen that its revenue results, though weak, has outperformed the industry average by 7.4% decline against 26.1% decline over the past 12 months. So generally it seems the industry isn’t doing well either.
A big weakness in STXS can be seen in its net profit margin of -30.89%. Although this is perfectly in-line wit the industry average, it is quite hurting. Interestingly, STXS has a very high gross profit margin, currently at 77.75%. In regard to cash flow, the company has had its figures diminish by 48.87% from a year ago. This signifies a decrease of $-2.14 million in operating cash flow.
STXS’ primary business is in the designing, manufacturing and marketing of cardiology control system. Its market is global. The company’s daily average volume over the past 30 days has been 2 million shares. It has a market capitalization of $70.55 million. It traded south on Thursday, October 24, dropping 4.93% to settle $4.82.
In the Wednesday’s trading, the stock went up nearly 42% in the regular trading, only to slip under its own weight the following day. Lack of trend is something that would make investors desires to study this stock more in the coming weeks.
